Eli Lilly and Company with price, financials, news flow, and insider context in one page.
Eli Lilly and Company is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where LLY sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
This page is structured for research context, not a trade call. It gives you a clean read on where LLY sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 19.8B | 7.4B | 2.8B |
| Q4 2025 | 19.29B | 6.64B | 254.2M |
| Q3 2025 | 17.6B | 5.58B | 6.03B |
| Q2 2025 | 15.56B | 5.66B | 1.28B |
(RTTNews) - Indian shares struggled for direction in early trade on Thursday as oil prices surged again on reports of fresh strikes on Iran and Federal Reserve Chair Kevin Warsh avoided giving any ...
Key PointsChipotle raised its full-year comparable sales forecast to low single digits.
US Central Command released a statement:At 10 p.m. ET on July 29, U.S. Central Command (CENTCOM) forces successfully completed a heavy wave of strikes against Iran in response to yesterday's attemp...
The Fed held interest rates steady, but long-term Treasury yields jumped. Investors are questioning whether he will act forcefully enough on inflation.
CNBC's Jim Cramer said software's sharp turnaround shows how quickly Wall Street can change its mind — and beaten-down AI infrastructure stocks could be next.
After the Dow falls by 1,000 points, the index typically is weak in the week that follows. The average then posts gains in the next month and three months.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Eli Lilly and Company (LLY) — questions investors ask
What is the current stock price of Eli Lilly and Company (LLY)?
Eli Lilly and Company (LLY) is trading at $1,154.97, down 4.55% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Eli Lilly and Company's market capitalization?
Eli Lilly and Company has a market capitalization of about 1.03T, derived from the latest share price and shares outstanding.
When is Eli Lilly and Company's next earnings date?
Eli Lilly and Company is next expected to report earnings on Aug 5, 2026. The LLY earnings page tracks the estimate and reporting history.
What is Eli Lilly and Company's P/E ratio?
Eli Lilly and Company trades at a forward price-to-earnings ratio of 25.63 — one measure of how the market is pricing its future earnings.
What is LLY's 52-week trading range?
Over the past 52 weeks, LLY has traded between $623.78 and $1,249.45.
What sector is Eli Lilly and Company in?
Eli Lilly and Company operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does Eli Lilly and Company pay a dividend?
Eli Lilly and Company currently carries a dividend yield of about 57.0%.
What is the analyst price target for LLY?
The mean analyst price target for LLY is $1,276.96, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This LLY page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.